Rane Sushil G, Cosenza Stephen C, Mettus Richard V, Reddy E Premkumar
Fels Institute for Cancer Research and Molecular Biology, Temple University School of Medicine, Philadelphia, Pennsylvania 19140, USA.
Mol Cell Biol. 2002 Jan;22(2):644-56. doi: 10.1128/MCB.22.2.644-656.2002.
Mutations in CDK4 and its key kinase inhibitor p16(INK4a) have been implicated in the genesis and progression of familial human melanoma. The importance of the CDK4 locus in human cancer first became evident following the identification of a germ line CDK4-Arg24Cys (R24C) mutation, which abolishes the ability of CDK4 to bind to p16(INK4a). To determine the role of the Cdk4(R24C) germ line mutation in the genesis of other cancer types, we introduced the R24C mutation in the Cdk4 locus of mice by using Cre-loxP-mediated "knock-in" technology. Cdk4(R24C/R24C) mouse embryo fibroblasts (MEFs) displayed increased Cdk4 kinase activity resulting in hyperphosphorylation of all three members of the Rb family, pRb, p107, and p130. MEFs derived from Cdk4(R24C/R24C) mice displayed decreased doubling times, escape from replicative senescence, and escape sensitivity to contact-induced growth arrest. These MEFs also exhibited a high degree of susceptibility to oncogene-induced transformation, suggesting that the Cdk4(R24C) mutation can serve as a primary event in the progression towards a fully transformed phenotype. In agreement with the in vitro data, homozygous Cdk4(R24C/R24C) mice developed tumors of various etiology within 8 to 10 months of their life span. The majority of these tumors were found in the pancreas, pituitary, brain, mammary tissue, and skin. In addition, Cdk4(R24C/R24C) mice showed extraordinary susceptibility to carcinogens and developed papillomas within the first 8 to 10 weeks following cutaneous application of the carcinogens 9,10-di-methyl-1,2-benz[a]anthracene (DMBA) and 12-O-tetradecanoylphorbol-13-acetate (TPA). This report formally establishes that the activation of Cdk4 is sufficient to promote cancer in many tissues. The observation that a wide variety of tumors develop in mice harboring the Cdk4(R24C) mutation offers a genetic proof that Cdk4 activation may constitute a central event in the genesis of many types of cancers in addition to melanoma.
细胞周期蛋白依赖性激酶4(CDK4)及其关键激酶抑制剂p16(INK4a)的突变与家族性人类黑色素瘤的发生和发展有关。在鉴定出一种种系CDK4-Arg24Cys(R24C)突变后,CDK4基因座在人类癌症中的重要性首次变得明显,该突变消除了CDK4与p16(INK4a)结合的能力。为了确定Cdk4(R24C)种系突变在其他癌症类型发生中的作用,我们使用Cre-loxP介导的“敲入”技术将R24C突变引入小鼠的Cdk4基因座。Cdk4(R24C/R24C)小鼠胚胎成纤维细胞(MEF)显示出Cdk4激酶活性增加,导致Rb家族的所有三个成员pRb、p107和p130过度磷酸化。来自Cdk4(R24C/R24C)小鼠的MEF显示出加倍时间缩短、逃避复制性衰老以及对接触诱导的生长停滞的逃避敏感性。这些MEF还表现出对癌基因诱导的转化高度敏感,这表明Cdk4(R24C)突变可能是向完全转化表型进展的主要事件。与体外数据一致,纯合Cdk4(R24C/R24C)小鼠在其寿命的8至10个月内发生了各种病因的肿瘤。这些肿瘤大多数发生在胰腺、垂体、脑、乳腺组织和皮肤中。此外,Cdk4(R24C/R24C)小鼠对致癌物表现出非凡的敏感性,并在皮肤应用致癌物9,10-二甲基-1,2-苯并[a]蒽(DMBA)和12-O-十四烷酰佛波醇-13-乙酸酯(TPA)后的前8至10周内发生乳头瘤。本报告正式确定Cdk4的激活足以在许多组织中促进癌症。携带Cdk4(R24C)突变的小鼠发生多种肿瘤的观察结果提供了遗传学证据,表明Cdk4激活除了在黑色素瘤中之外,可能是许多类型癌症发生的核心事件。